2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Wednesday, November 16, 2016

11:00AM-12:30PM: Abstract Number: 3231

miR200b-5p Expression in Minor Salivary Glands (MSG): A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?

Sjögren's Syndrome II: Basic Insights

11:00AM-12:30PM: Abstract Number: 3227

Modelling Primary Sjögren’s Syndrome Using Salivary Gland Stem Cells

Sjögren's Syndrome II: Basic Insights

11:00AM-12:30PM: Abstract Number: 3244

Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3189

Patient Perceptions of Glucocorticoid Side Effects: A Survey of Users in an Online Health Community

Epidemiology and Public Health III: Psoriatic Arthritis and More

11:00AM-12:30PM: Abstract Number: 3195

Patterns and Predictors of Hydroxychloroquine Nonadherence in a Nationwide Cohort of Medicaid Beneficiaries with Systemic Lupus Erythematosus

Health Services Research II

11:00AM-12:30PM: Abstract Number: 3246

Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3208

Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Autoinflammatory Diseases and Juvenile Dermatomyositis

11:00AM-12:30PM: Abstract Number: 3234

Prevalence and Metric of Depression and Anxiety in Lupus: A Systematic Review and Meta-Analys

Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Quality of Life

11:00AM-12:30PM: Abstract Number: 3237

Responsiveness and Its Magnitude in the 36-Item Short Form Health Survey and the Lupus Quality of Life Questionnaire in Patients with Active Disease

Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Quality of Life

11:00AM-12:30PM: Abstract Number: 3247

Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3185

Sensitivity Analysis for the Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients

Epidemiology and Public Health III: Psoriatic Arthritis and More

11:00AM-12:30PM: Abstract Number: 3250

Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3251

Sleep and Physical Activity: A Nationwide Survey Among People with Rheumatic Disease in Ireland

ARHP VI: Rehabilitation Sciences

11:00AM-12:30PM: Abstract Number: 3187

Societal Costs and Patients’ Experience of Health Inequities from Psoriatic Arthritis: A Danish Cohort Study

Epidemiology and Public Health III: Psoriatic Arthritis and More

11:00AM-12:30PM: Abstract Number: 3236

Socio-Demographic and Clinical Factors Influencing Generic and Disease-Specific Quality of Life in Patients with Systemic Lupus Erythematosus: Results of a Prospective Multicenter Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Quality of Life

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].